Zopiclone to Geriatric Patients

Dehlin, Ove; Rundgren, Åke; Börjesson, Lennart; Ekelund, P.; Gatzinska, R; Hedenrud, B; Mellström, Dan

doi:10.1159/000137924

Cited by 12 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in a recent systematic review, assessments on older adults using zolpidem during night time and/or next-morning awakening pointed to minimal or no losses in psychometric and/or psychomotor performance [68]. Likewise, the literature also presents evidence that cognitive and psychomotor functions as well as alertness on waking do not appear to be substantially impacted by the use of zopiclone [54,[69][70][71]. Despite of (or owing to) the controversy, zopiclone and zolpidem present pharmacological issues regarding tolerability and safety that cannot be neglected and deserve further investigation, being so far comparable in frequency and intensity to those of BZDs as evidenced by studies elsewhere [72][73][74], and with use of all these drug classes intended to be personalized, implemented with caution, and under watchful surveillance.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial

Louzada

Machado

Quintas

et al. 2021

Neuropsychopharmacol.

View full text Add to dashboard Cite

No prior studies have evaluated the efficacy and safety of zolpidem and zopiclone to treat insomnia of demented patients. This randomized, triple-blind, placebo-controlled clinical trial used these drugs to treat patients with probable, late onset Alzheimer's dementia (AD) (DSM V and NINCDS-ADRDA criteria) exhibiting insomnia (DSM V criteria and nocturnal NPI scores ≥ 2). Actigraphic records were performed for 7 days at baseline and for 14 days during the treatment period in 62 patients aged 80.5 years in average and randomized at a 1:1:1 ratio for administration of zolpidem 10 mg/day, zopiclone 7.5 mg/day or placebo. Primary endpoint was the main nocturnal sleep duration (MNSD), whereas secondary outcomes were the proportion of the night time slept, awake time after sleep onset (WASO), nocturnal awakenings, total daytime sleep time and daytime naps. Cognitive and functional domains were tested before and after drug/placebo use. Three participants under zopiclone use had intervention interrupted due to intense daytime sedation and worsened agitation with wandering. Zopiclone produced an 81 min increase in MNSD (95% confidence interval (CI): −0.8, 163.2), a 26 min reduction in WASO (95% CI: −56.2, 4.8) and a 2-episode decrease in awakening per night (95% CI: −4.0, 0.4) in average compared to placebo. Zolpidem yielded no significant difference in MNSD despite a significant 22 min reduction in WASO (95% CI: −52.5, 8.3) and a reduction of 1 awakening each night (95% CI: −3.4, 1.2) in relation to placebo. There was a 1-point reduction in mean performance in the symbols search test among zolpidem users (95% CI: −4.1, 1.5) and an almost eight-point reduction in average scores in the digit-symbol coding test among zopiclone users (95% CI: −21.7, 6.2). In summary, short-term use of zolpidem or zopiclone by older insomniacs with AD appears to be clinically helpful, even though safety and tolerance remain issues to be personalized in healthcare settings and further investigated in subsequent trials. This trial was registered in ClinicalTrials.gov Identifier: NCT03075241.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial

Louzada

Machado

Quintas

et al. 2021

Neuropsychopharmacol.

View full text Add to dashboard Cite

show abstract

Comparison of zopiclone and flurazepam treatments in insomnia

Singh

Bourgouin

1990

Human Psychopharmacology

View full text Add to dashboard Cite

In this double-blind study the efficacy and safety of two doses (7.5 and 11.25 mg) of zopiclone were compared to that of flurazepam (30mg) in 60 insomniac patients divided into three groups. After an initial 4-day washout period, placebo was administered single-blind to all patients followed by 24 consecutive days of either one of the three drug levels. No significant difference was shown between the two zopiclone dosages at any time during the study for sleep efficacy and psychomotor performance. Compared to flurazepam, zopiclone was slightly less effective for sleep induction and sleep soundness variables. However, flurazepam was constantly worse than zopiclone for daytime performance. This study shows that both zopiclone dosages are shown to be active and safe in the treatment of insomnia, and exhibit a true advantage over flurazepam by its low incidence of residual effects.

show abstract

Efficacy and Safety of Zopiclone and Eszopiclone in the Treatment of Primary and Comorbid Insomnia

Najib

2010

GABA and Sleep

View full text Add to dashboard Cite

Zopiclone to Geriatric Patients

Cited by 12 publications

References 11 publications

The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial

The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial

Comparison of zopiclone and flurazepam treatments in insomnia

Efficacy and Safety of Zopiclone and Eszopiclone in the Treatment of Primary and Comorbid Insomnia

Contact Info

Product

Resources

About